The attachment protein “spike” of the new coronavirus SARS-CoV-2 uses the same cellular attachment factor (ACE2) as SARS-CoV and uses the cellular protease TMPRSS2 for its activation. Existing, clinically approved drugs directed against TMPRSS2 inhibit SARS-CoV-2 infection of lung cells. Illustration: Markus Hoffmann
Göttingen infection researchers identify potential drug
Viruses must enter cells of the human body to cause disease. For this, they attach to suitable cells and inject their genetic information into these cells. Infection biologists from the German Primate Center – Leibniz Institute for Primate Research in Göttingen, together with colleagues at Charité – Universitätsmedizin Berlin, have investigated how the novel coronavirus SARS-CoV-2 penetrates cells. They have identified a cellular enzyme that is essential for viral entry into lung cells: the protease TMPRSS2. A clinically proven drug known to be active against TMPRSS2 was found to block SARS-CoV-2 infection and might constitute a novel treatment option (Cell).
Several coronaviruses circulate worldwide and constantly infect humans, which normally caused only mild respiratory disease. Currently, however, we are witnessing a worldwide spread of a new coronavirus with more than 90,000 confirmed cases and over 3,000 deaths. The new virus has been named SARS coronavirus-2 and has been transmitted from animals to humans. It causes a respiratory disease called COVID-19 that may take a severe course. The SARS coronavirus-2 has been spreading since December 2019 and is closely related to the SARS coronavirus that caused the SARS pandemic in 2002/2003. No vaccines or drugs are currently available to combat these viruses.
Stopping virus spread
A team of scientists led by infection biologists from the German Primate Centre and including researchers from Charité, the University of Veterinary Medicine Hannover Foundation, the BG-Unfallklinik Murnau, the LMU Munich, the Robert Koch Institute and the German Center for Infection Research, wanted to find out how the new coronavirus SARS-CoV-2 enters host cells and how this process can be blocked. The researchers identified a cellular protein that is important for the entry of SARS-CoV-2 into lung cells. “Our results show that SARS-CoV-2 requires the protease TMPRSS2, which is present in the human body, to enter cells,” says Stefan Pöhlmann, head of the Infection Biology Unit at the German Primate Center. “This protease is a potential target for therapeutic intervention.”
Since it is known that the drug camostat mesilate inhibits the protease TMPRSS2, the researchers have investigated whether it can also prevent infection with SARS-CoV-2. “We have tested SARS-CoV-2 isolated from a patient and found that camostat mesilate blocks entry of the virus into lung cells,” says Markus Hoffmann, the lead author of the study. Camostat mesilate is a drug approved in Japan for use in pancreatic inflammation. “Our results suggest that camostat mesilate might also protect against COVID-19,” says Markus Hoffmann. “This should be investigated in clinical trials.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Coronavirus live news: Finland announces lockdown plan; Ukraine registers 40% jump in new caseson February 25, 2021 at 2:32 am
EU leaders to debate certificates for people who had Covid jabs; Olympic torch audience asked to applaud rather than cheer passing runners; Israeli researchers took data from 1.2 million people for Pf ...
- Covid-19 Live Updates: Deaths in California Surpass 50,000on February 25, 2021 at 2:11 am
The state accounts for roughly one in 10 of the coronavirus-related deaths recorded in the U.S. A new variant spreading in New York City is being closely studied by scientists.
- China denies subjecting US diplomats to COVID-19 anal testson February 25, 2021 at 1:44 am
China has denied subjecting U.S. diplomats to COVID-19 anal tests following reports from Washington that some of its personnel have been forced to undergo the procedure ...
- Federal funeral aid for Covid-19 victims stalls over scam fearson February 25, 2021 at 1:41 am
The Federal Emergency Management Agency is set to dole out cash to families of Americans who died of Covid-19, but there is potential for widespread fraud.
- Despite US Covid-19 cases dropping, infections are still staggeringly high. Here's what has experts worriedon February 25, 2021 at 1:29 am
A new ensemble forecast published Wednesday by the Centers for Disease Control and Prevention suggests the daily Covid-19 death rate will slow in the coming weeks -- good news following more than a ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- camostat mesilateon February 16, 2021 at 6:05 am
An additional arm will test the drug camostat mesilate, a protease inhibitor that can block the TMPRSS2 host protein that is necessary for viral entry into human cells. ACTIV-3: This Phase 3 trial is ...
- Sensor Enables Fast, Accurate and Cheap Detection of Multiple Sepsis Biomarkerson February 15, 2021 at 6:50 am
These include SNG001, an inhalable beta interferon; AZD7442, a long-acting monoclonal antibody combination; and Camostat mesilate, an orally administered serine protease inhibitor.
- Four potential COVID-19 therapeutics enter Phase 2/3 testingon February 15, 2021 at 6:44 am
Enrollment has begun to test additional investigational drugs in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV ...
- Experts Discuss SARS-CoV-2 Viral Variantson February 15, 2021 at 2:24 am
Scientists from the NIAID outline how SARS-CoV-2 variants have arisen, concerns about whether vaccines currently authorized for use will continue to protect against new variants, and the need for a ...
- Voya Investment Management Invests $4.6 Billion of Private Placement Debt In 2020on February 12, 2021 at 8:04 am
Voya Investment Management (Voya IM), the asset management business of Voya Financial, Inc. , announced today that it committed $4.6 billion of debt across private placement investments in 2020. This ...